Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Helix BioPharmaHBPCF 28 Equity-to-Asset is 0.69 as of Apr. 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100. Among 1,414 Biotechnology companies, Helix BioPharma ranks better than 51.27% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Helix BioPharma's Total Stockholders Equity for the quarter that ended in Apr. 2026 was $10.68 Mil. Helix BioPharma's Total Assets for the quarter that ended in Apr. 2026 was $15.55 Mil.
The historical rank and industry rank for Helix BioPharma's Equity-to-Asset or its related term are showing as below:
HBPCF'
s Equity-to-Asset Range Over the Past 10 Years
Min: -4.34 Med: -0.01 Max: 0.86
Current: 0.69
During the past 13 years, the highest Equity to Asset Ratio of Helix BioPharma was 0.86. The lowest was -4.34. And the median was -0.01.
HBPCF's Equity-to-Asset is ranked better than 51.27% of 1414
companies
in the Biotechnology industry
Industry Median: 0.68
vs HBPCF: 0.69
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Helix BioPharma Equity-to-Asset Related Terms
Helix BioPharma Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Helix BioPharma's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBPCF vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Helix BioPharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helix BioPharma Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helix BioPharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Helix BioPharma's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Helix BioPharma's Equity to Asset Ratio for the fiscal year that ended in Jul. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helix BioPharma (HBPCF) has a Equity-to-Asset of 0.69 as of Apr. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Helix BioPharma and its competitors. According to the industry distribution chart, Helix BioPharma ranks #689 out of 1414 companies in the Biotechnology industry, placing it in the top 48.7%.
Is Helix BioPharma's Equity-to-Asset too high?
Helix BioPharma's current Equity-to-Asset is 0.69. The Biotechnology industry median Equity-to-Asset is 0.68. Helix BioPharma's value of 0.69 is 1.5% above this industry median. Based on the distribution chart, Helix BioPharma ranks #689 out of 1414 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helix BioPharma ranks #689 out of 1414 companies for Equity-to-Asset. This puts Helix BioPharma in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Helix BioPharma's value of 0.69 is 1.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Helix BioPharma's current Equity-to-Asset of 0.69 is 1.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Helix BioPharma and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Helix BioPharma's current Equity-to-Asset is 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current Equity-to-Asset of 0.69. The current Equity-to-Asset is 0.69 and 1.5% above the Biotechnology industry median of 0.68. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current Equity-to-Asset is 0.69 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score
Get the complete analysis for HBPCF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBPCF has been successfully added to your 
